Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.
Identifieur interne : 001D65 ( PubMed/Checkpoint ); précédent : 001D64; suivant : 001D66Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.
Auteurs : E K Morgen [Canada] ; H-J Lenz [États-Unis] ; D J Jonker [Canada] ; D. Tu [Canada] ; G. Milano [France] ; F. Graziano [Italie] ; J. Zalcberg [Australie] ; C S Karapetis [Australie] ; A. Dobrovic [Australie] ; C J O'Callaghan [Canada] ; G. Liu [Canada]Source :
- The pharmacogenomics journal [ 1473-1150 ] ; 2016.
Abstract
Studies of germline polymorphisms as predictors of tumor response to anti-epidermal growth factor receptor (EGFR) monoclonal antibody agents in metastatic colorectal cancer have reported inconsistent results. We performed a systematic review of studies from 1990 to September 2015, followed by random-effects meta-analyses for polymorphisms examined in at least three studies. Of 87 studies, 40 passed the criteria for systematic review and 23 for meta-analysis. The polymorphisms suitable for meta-analysis were CCND1 (rs17852153), COX2 (rs20417), EGF (rs4444903), EGFR (rs712829, rs11543848, 3'UTR CA repeat), FCGR2A (rs1801274), FCGR3A (rs396991), IL8 (rs4073), KRAS (rs61764370) and VEGFA (rs3025039). Meta-analysis yielded nominal significance (at α=0.05) for rs4444903 and rs11543848, but showed no significant results after multiple testing correction; this was unchanged by sensitivity analyses to address subgroups, funnel-plot asymmetries, and study quality. This highlights a tendency for lack of replication in the face of initial positive results, and possibly the unsuitability of relying on tumor response as a surrogate marker in this setting.The Pharmacogenomics Journal advance online publication, 29 November 2016; doi:10.1038/tpj.2016.56.
DOI: 10.1038/tpj.2016.56
PubMed: 27897268
Affiliations:
- Australie, Canada, France, Italie, États-Unis
- Californie, Ontario, Provence-Alpes-Côte d'Azur
- Nice, Toronto
- Université de Toronto
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:27897268Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.</title><author><name sortKey="Morgen, E K" sort="Morgen, E K" uniqKey="Morgen E" first="E K" last="Morgen">E K Morgen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Lenz, H J" sort="Lenz, H J" uniqKey="Lenz H" first="H-J" last="Lenz">H-J Lenz</name><affiliation wicri:level="2"><nlm:affiliation>USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>USC/Norris Comprehensive Cancer Center, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Jonker, D J" sort="Jonker, D J" uniqKey="Jonker D" first="D J" last="Jonker">D J Jonker</name><affiliation wicri:level="1"><nlm:affiliation>The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Tu, D" sort="Tu, D" uniqKey="Tu D" first="D" last="Tu">D. Tu</name><affiliation wicri:level="1"><nlm:affiliation>Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Canadian Cancer Trials Group, Queen's University, Kingston, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Milano, G" sort="Milano, G" uniqKey="Milano G" first="G" last="Milano">G. Milano</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Oncopharmacologie EA 3836, Centre Antoine Lacassagne, Nice, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Oncopharmacologie EA 3836, Centre Antoine Lacassagne, Nice</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Graziano, F" sort="Graziano, F" uniqKey="Graziano F" first="F" last="Graziano">F. Graziano</name><affiliation wicri:level="1"><nlm:affiliation>Division of Medical Oncology, Azienda "Ospedali Riuniti Marche Nord", Pesaro, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Medical Oncology, Azienda "Ospedali Riuniti Marche Nord", Pesaro</wicri:regionArea><wicri:noRegion>Pesaro</wicri:noRegion></affiliation></author><author><name sortKey="Zalcberg, J" sort="Zalcberg, J" uniqKey="Zalcberg J" first="J" last="Zalcberg">J. Zalcberg</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Program, School of Public Health and Preventive Medicine, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Program, School of Public Health and Preventive Medicine, Faculty of Medicine, Monash University, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Karapetis, C S" sort="Karapetis, C S" uniqKey="Karapetis C" first="C S" last="Karapetis">C S Karapetis</name><affiliation wicri:level="1"><nlm:affiliation>Flinders University and Flinders Medical Centre, Adelaide, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Flinders University and Flinders Medical Centre, Adelaide, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Dobrovic, A" sort="Dobrovic, A" uniqKey="Dobrovic A" first="A" last="Dobrovic">A. Dobrovic</name><affiliation wicri:level="1"><nlm:affiliation>Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="O Callaghan, C J" sort="O Callaghan, C J" uniqKey="O Callaghan C" first="C J" last="O'Callaghan">C J O'Callaghan</name><affiliation wicri:level="1"><nlm:affiliation>Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Canadian Cancer Trials Group, Queen's University, Kingston, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Liu, G" sort="Liu, G" uniqKey="Liu G" first="G" last="Liu">G. Liu</name><affiliation wicri:level="4"><nlm:affiliation>Departments of Medicine and Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Medicine and Medical Biophysics, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27897268</idno><idno type="pmid">27897268</idno><idno type="doi">10.1038/tpj.2016.56</idno><idno type="wicri:Area/PubMed/Corpus">001638</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001638</idno><idno type="wicri:Area/PubMed/Curation">001616</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001616</idno><idno type="wicri:Area/PubMed/Checkpoint">001616</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001616</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.</title><author><name sortKey="Morgen, E K" sort="Morgen, E K" uniqKey="Morgen E" first="E K" last="Morgen">E K Morgen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Lenz, H J" sort="Lenz, H J" uniqKey="Lenz H" first="H-J" last="Lenz">H-J Lenz</name><affiliation wicri:level="2"><nlm:affiliation>USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>USC/Norris Comprehensive Cancer Center, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Jonker, D J" sort="Jonker, D J" uniqKey="Jonker D" first="D J" last="Jonker">D J Jonker</name><affiliation wicri:level="1"><nlm:affiliation>The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Tu, D" sort="Tu, D" uniqKey="Tu D" first="D" last="Tu">D. Tu</name><affiliation wicri:level="1"><nlm:affiliation>Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Canadian Cancer Trials Group, Queen's University, Kingston, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Milano, G" sort="Milano, G" uniqKey="Milano G" first="G" last="Milano">G. Milano</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Oncopharmacologie EA 3836, Centre Antoine Lacassagne, Nice, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Oncopharmacologie EA 3836, Centre Antoine Lacassagne, Nice</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Graziano, F" sort="Graziano, F" uniqKey="Graziano F" first="F" last="Graziano">F. Graziano</name><affiliation wicri:level="1"><nlm:affiliation>Division of Medical Oncology, Azienda "Ospedali Riuniti Marche Nord", Pesaro, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Medical Oncology, Azienda "Ospedali Riuniti Marche Nord", Pesaro</wicri:regionArea><wicri:noRegion>Pesaro</wicri:noRegion></affiliation></author><author><name sortKey="Zalcberg, J" sort="Zalcberg, J" uniqKey="Zalcberg J" first="J" last="Zalcberg">J. Zalcberg</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Program, School of Public Health and Preventive Medicine, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Program, School of Public Health and Preventive Medicine, Faculty of Medicine, Monash University, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Karapetis, C S" sort="Karapetis, C S" uniqKey="Karapetis C" first="C S" last="Karapetis">C S Karapetis</name><affiliation wicri:level="1"><nlm:affiliation>Flinders University and Flinders Medical Centre, Adelaide, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Flinders University and Flinders Medical Centre, Adelaide, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Dobrovic, A" sort="Dobrovic, A" uniqKey="Dobrovic A" first="A" last="Dobrovic">A. Dobrovic</name><affiliation wicri:level="1"><nlm:affiliation>Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="O Callaghan, C J" sort="O Callaghan, C J" uniqKey="O Callaghan C" first="C J" last="O'Callaghan">C J O'Callaghan</name><affiliation wicri:level="1"><nlm:affiliation>Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Canadian Cancer Trials Group, Queen's University, Kingston, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Liu, G" sort="Liu, G" uniqKey="Liu G" first="G" last="Liu">G. Liu</name><affiliation wicri:level="4"><nlm:affiliation>Departments of Medicine and Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Medicine and Medical Biophysics, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><series><title level="j">The pharmacogenomics journal</title><idno type="eISSN">1473-1150</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Studies of germline polymorphisms as predictors of tumor response to anti-epidermal growth factor receptor (EGFR) monoclonal antibody agents in metastatic colorectal cancer have reported inconsistent results. We performed a systematic review of studies from 1990 to September 2015, followed by random-effects meta-analyses for polymorphisms examined in at least three studies. Of 87 studies, 40 passed the criteria for systematic review and 23 for meta-analysis. The polymorphisms suitable for meta-analysis were CCND1 (rs17852153), COX2 (rs20417), EGF (rs4444903), EGFR (rs712829, rs11543848, 3'UTR CA repeat), FCGR2A (rs1801274), FCGR3A (rs396991), IL8 (rs4073), KRAS (rs61764370) and VEGFA (rs3025039). Meta-analysis yielded nominal significance (at α=0.05) for rs4444903 and rs11543848, but showed no significant results after multiple testing correction; this was unchanged by sensitivity analyses to address subgroups, funnel-plot asymmetries, and study quality. This highlights a tendency for lack of replication in the face of initial positive results, and possibly the unsuitability of relying on tumor response as a surrogate marker in this setting.The Pharmacogenomics Journal advance online publication, 29 November 2016; doi:10.1038/tpj.2016.56.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">27897268</PMID><DateCreated><Year>2016</Year><Month>11</Month><Day>29</Day></DateCreated><DateRevised><Year>2016</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-1150</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2016</Year><Month>Nov</Month><Day>29</Day></PubDate></JournalIssue><Title>The pharmacogenomics journal</Title><ISOAbbreviation>Pharmacogenomics J.</ISOAbbreviation></Journal><ArticleTitle>Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/tpj.2016.56</ELocationID><Abstract><AbstractText>Studies of germline polymorphisms as predictors of tumor response to anti-epidermal growth factor receptor (EGFR) monoclonal antibody agents in metastatic colorectal cancer have reported inconsistent results. We performed a systematic review of studies from 1990 to September 2015, followed by random-effects meta-analyses for polymorphisms examined in at least three studies. Of 87 studies, 40 passed the criteria for systematic review and 23 for meta-analysis. The polymorphisms suitable for meta-analysis were CCND1 (rs17852153), COX2 (rs20417), EGF (rs4444903), EGFR (rs712829, rs11543848, 3'UTR CA repeat), FCGR2A (rs1801274), FCGR3A (rs396991), IL8 (rs4073), KRAS (rs61764370) and VEGFA (rs3025039). Meta-analysis yielded nominal significance (at α=0.05) for rs4444903 and rs11543848, but showed no significant results after multiple testing correction; this was unchanged by sensitivity analyses to address subgroups, funnel-plot asymmetries, and study quality. This highlights a tendency for lack of replication in the face of initial positive results, and possibly the unsuitability of relying on tumor response as a surrogate marker in this setting.The Pharmacogenomics Journal advance online publication, 29 November 2016; doi:10.1038/tpj.2016.56.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morgen</LastName><ForeName>E K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathobiology and Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenz</LastName><ForeName>H-J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonker</LastName><ForeName>D J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milano</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratoire d'Oncopharmacologie EA 3836, Centre Antoine Lacassagne, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graziano</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Azienda "Ospedali Riuniti Marche Nord", Pesaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zalcberg</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cancer Research Program, School of Public Health and Preventive Medicine, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karapetis</LastName><ForeName>C S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Flinders University and Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobrovic</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Callaghan</LastName><ForeName>C J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Departments of Medicine and Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacogenomics J</MedlineTA><NlmUniqueID>101083949</NlmUniqueID><ISSNLinking>1470-269X</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>05</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>05</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27897268</ArticleId><ArticleId IdType="pii">tpj201656</ArticleId><ArticleId IdType="doi">10.1038/tpj.2016.56</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Canada</li><li>France</li><li>Italie</li><li>États-Unis</li></country><region><li>Californie</li><li>Ontario</li><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Nice</li><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Morgen, E K" sort="Morgen, E K" uniqKey="Morgen E" first="E K" last="Morgen">E K Morgen</name></noRegion><name sortKey="Jonker, D J" sort="Jonker, D J" uniqKey="Jonker D" first="D J" last="Jonker">D J Jonker</name><name sortKey="Liu, G" sort="Liu, G" uniqKey="Liu G" first="G" last="Liu">G. Liu</name><name sortKey="O Callaghan, C J" sort="O Callaghan, C J" uniqKey="O Callaghan C" first="C J" last="O'Callaghan">C J O'Callaghan</name><name sortKey="Tu, D" sort="Tu, D" uniqKey="Tu D" first="D" last="Tu">D. Tu</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Lenz, H J" sort="Lenz, H J" uniqKey="Lenz H" first="H-J" last="Lenz">H-J Lenz</name></region></country><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Milano, G" sort="Milano, G" uniqKey="Milano G" first="G" last="Milano">G. Milano</name></region></country><country name="Italie"><noRegion><name sortKey="Graziano, F" sort="Graziano, F" uniqKey="Graziano F" first="F" last="Graziano">F. Graziano</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Zalcberg, J" sort="Zalcberg, J" uniqKey="Zalcberg J" first="J" last="Zalcberg">J. Zalcberg</name></noRegion><name sortKey="Dobrovic, A" sort="Dobrovic, A" uniqKey="Dobrovic A" first="A" last="Dobrovic">A. Dobrovic</name><name sortKey="Karapetis, C S" sort="Karapetis, C S" uniqKey="Karapetis C" first="C S" last="Karapetis">C S Karapetis</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001D65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:27897268
|texte= Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:27897268" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |